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Abstract. Cystic echinococcosis (CE) is a chronic, complex, and overlooked zoonotic disease caused by Echino-
coccus granulosus. In humans, it may result in a wide spectrum of clinical manifestations depending on the type of
complications, ranging from asymptomatic infection to fatal disease. The primary complications and risk factors asso-
ciated with CE are not well defined. We performed a retrospective, observational study of inpatients diagnosed with CE
fromJanuary 1998 toDecember 2017 in the public health-care systemofwestern Spain. Five hundred and six caseswere
analyzed. More than half of the patients (302 [59.7%]) were asymptomatic, and the diagnoses were made incidentally. A
total of 204 (40.3%) patients had complications associated with CE; 97 (47.5%) were mechanical, 62 (30.4%) were
infectious, 15 (7.3%) were immunoallergic, and 30 (14.7%) involved a combination of complications. Mortality was higher
in patientswithmechanical complications (9.4%) than inpatientswith infectious complications (5.6%) and inpatientswith
allergic complications (0%) (odds ratio = 19.7, 95% CI, 4.3–89.1, P < 0.001). In summary, CE frequently results in
complications, especially in the liver in younger patients and, regardless of other variables, such as size or stage of cyst.
Mechanical problems and superinfection are the most frequent complications. CE is an obligatory diagnosis in patients
with urticarial or anaphylactoid reactions of unknown cause in endemic areas.
INTRODUCTION
Cystic echinococcosis (CE) is a parasitic disease with a
worldwide distribution caused by the larval forms of the
tapeworm Echinococcus.1 Echinococcus granulosus sensu
lato and E. multilocularis are the most important species be-
cause of their geographical distribution and economic impact
worldwide, causing CE and alveolar echinococcosis, re-
spectively. Eurasia, Africa, Australia, and South America are
the areaswith the highest prevalenceofCE,mainly becauseof
sheep farming. CE in Europe is prevalent in countries around
the Mediterranean, such as Greece, Italy, Portugal, and
Spain.2 In Spain, the most affected regions were those of the
northeastern, central, and western parts of the country (the
autonomous regions of Aragon, Castile-La Mancha, Castile-
Leon, Extremadura, Navarre, and La Rioja), where human CE
incidence rates range from 1.1 to 3.4 cases per 105 inhabi-
tants, as well as ovine/bovine CE prevalence rates of up to
23% are observed.3,4 Human infection causes cyst growth in
anyorgan; themost common locations are the liver (> 65%)and
lungs (25%). Spanish authors such as Hidalgo Pascual et al.5
and Pozo et al.6 describe the clinical course of CE in previous
works. Cysts can grow approximately 1–50 mm/year and per-
sist unchangedover the years, or theymayexhibit spontaneous
rupture, collapse, and disappear.7 The initial phase of primary
infection is most often asymptomatic. Many infections are ac-
quired in childhood but do not cause clinical manifestations
until adulthood. Latency of more than 50 years before symp-
toms arise has been reported, whereas approximately 50% of
detected cases occur in asymptomatic patients.8,9 Moreover,
other cases remain undiagnosed or are incidentally found
duringautopsy.10On theotherhand,CEcan frequentlybecome
complicated, causingseveralmanifestations, includingdeath.11
Complications frequently occur secondary to CE treatment,
which is associated with surgical interventions or other thera-
peutic procedures, such as puncture, aspiration, injection,
reaspiration.12,13 Moreover, primary complications have also
been frequently described in the literature because of rupture of
the cyst, superinfection, or immunological reactions. Never-
theless, the data on the incidence of these complications and
the associated risk factors havenot beenwell defined.Thus, the
aim of this study was to analyze the primary complications as
related to initial presentation in patients hospitalized with CE
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during the years 1998–2017 in a tertiary hospital to define the
frequency and the risk factors involved with CE.
Patients and methods. The design was a descriptive ret-
rospective study. We reviewed all patients diagnosed with
CE according to the ICD-9 (code 122.0 to 122.9) criteria who
were admitted to the Complejo Asistencial Universitario de
Salamanca (CAUSA) between January 1998 and December
2017. Complejo Asistencial Universitario de Salamanca is a
tertiary care hospital; it covers an area of 12,350 km2 with
333,603 inhabitants as of 2017 (National Institute of Statis-
tics (INE; http://www.ine.es/),14 and it is located in western
Spain. The initial screening of patients was carried out using
the Hospital Discharge Reports. It is an official and manda-
tory document that summarizes hospital care after admis-
sion and includes final diagnoses, the procedures used, and
the main recommendations that the patient should follow.
The clinical and epidemiological data were collected after
review of themedical records. A data collection protocol was
designed to collect data frommedical records. We defined a
primary complication of CE if a patient with CE presented
with a symptom or sign attributable to CE. Patients with
complications secondary to the surgical or other treatments
for CE and those with missing data were excluded from the
study. The Ethics Committee of CAUSA approved this study.
All the data analyzed were anonymous.
Statistical analysis. The results are expressed as fre-
quencies for categorical variables and as the mean and ±SD
for continuous variables. A chi-square test was used to
compare the association between the categorical variables,
such as the clinical and demographic variables, and the
measured outcomes are expressed as the odds ratios (ORs)
together with the 95% CIs. The continuous variables were
compared with Student’s t-test or the Mann–Whitney test for
two groups, depending on their normal or non-normal distri-
bution, respectively. In addition, we applied corresponding
regression models for the multivariate analysis. We consid-
ered a statistically significant difference at a P-value < 0.05.
The annual/period incidence rate of CE was calculated by
dividing the number of new cases observed in the defined
period (1 year or 20 years) by the total disease-free periods of
disease-person time during the observation period defined in
the study, multiplied by 100,000 and expressed as “cases per
105 person-years.” As it is not possible to accurately measure
disease-free periods, the total figure of person-time at risk can
be approximately estimated and is satisfactory when the size
of the population is stable; therefore, the estimate is achieved
FIGURE 1. Participant profile.
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by multiplying the average population size studied by the
duration of the observation period. Thus, the denominators
were obtained from population counts for each year at the
municipality level of the National Institute of Statistics. All of
the data were analyzed with SPSS 23.0 (Statistical Package
for the Social Sciences, IBM Corp., Armonk, NY).
RESULTS
Main data. Between January 1998 and December 2017,
594 patients with new CE-related diagnosis codes 122.0 to
122.9were registered at CAUSA, and 88 (14.8%) patientswith
missing data were excluded from the study. Figure 1 shows
the flowchart of participants in the study. A total of 506 pa-
tients met the inclusion criteria. Table 1 shows the primary
data of patients with CE.
A total of 302 (59.7%) patients were asymptomatic at the
time of diagnosis or during the follow-up, and the diagnosis in
these cases was made incidentally. In total, 204 (40.3%) pa-
tients presented clinical data that suggested different com-
plications of CE (Figure 2). The incidence rate during the study
period (1998–2017) was 2.93 cases ×105 person-years.
Figure 3 shows the progression of the annual incidence
rates of CE complications over the 20 years.
Risk factors for complications. Younger patients (< 60
years old) show a higher risk complication than older patients
did (45.1% vs. 36.8%, P = 0.058). Table 2 shows the
association analysis between the risk factors and types of
complications. Allergic complications were more frequent in
younger patients (< 60 years old) than in older patients (88.2%
vs. 11.8%, respectively, [OR = 10.8, 95% CI, 2.4–47.7, P <
0.001] and in patients from urban areas than in patients from
rural areas (58.8% vs. 41.2%, respectively) [OR = 1.6, 95%CI,
1.1–2.4,P=0.014]. The liverwas themost common location of
cysts among the three groups of patients based on compli-
cations, and the incidence percentages showed significant
differences. A total of 94.1% of patients had liver cysts in the
allergic complications group, 83.3% in the infectious com-
plications group, and 68.5% in the mechanical complications
group (P < 0.001). In patients with allergic complications, the
percentage of patients with multiple cysts was higher (52.9%,
P = 0.050) than that of patients with infectious complications
(28.9%) and of patients with mechanical complications
(32.3%). In these patients, single cysts were more commonly
detected.Wedid not finda statistically significant difference in
the complication of CE in variables such as cyst size or WHO
classification (P < 0.05).
Mechanical complications. In our cohort, themacroscopic
rupture of CE and secondary fistula were the most frequent
complications detected in 17.4% (88) of the patients (Table 3).
The most frequent fistulas were biliocystic in 68/88 (77.2%)
patients, followed by bronchial fistulas in 12/88 (13.6%) cases,
pleural fistulas in 6/88 (6.8%) cases, and pericardial and cuta-
neous in 1/88 (1.14%) patient with liver and thoracic CE.
The patients who had biliary fistulas manifested jaundice
and abdominal pain (32/88, 36.7%). The patients with bron-
chial fistulas had vomiting (7/12, 58.3%), and the patients with
bronchial, pleural, or pericardial fistulas presented thoracic
pain (3) and dyspnea (4). Most patients with fistulas (84/88,
95.5%) were treated surgically, either by surgery alone (34/88,
38.6%) or surgery and drugs (50/88, 56.8%) (OR = 9.3, 95%
CI, 3.3–26.1, P < 0.001]. Four patients decided to “watch and
wait.” There were 8/88 (9.1%) deaths among patients with
fistulas, and 4/88 (4.5%) deaths were caused by CE.
Twenty-eight (5.5%) patients had compression with dis-
placement of adjacent structures (18/28, 64.3%) or obstruc-
tion (10/28, 35.7%). The cysts ruptured in 15 (2.9%) patients.
Two patients with liver CE presented with complications
such as portal hypertension. Both patients presented with
portal cavernomatosis, and they were free from other liver
diseases. A total of two patients presented with variceal
hemorrhage and one patient had ascites.
In the lungs, 1/71 (1.4%) patients showed a medium lobe
collapse caused by CE displacement. One of two (50%) pa-
tients presented medullary section syndrome secondary to
intramedullary CE.
Infectious complications.Coinfections associatedwithCE
weredetected in17.8% (90) of patients (Table2); 28/90patients
had fistulas (OR = 2.6, 95%CI, 1.5–4.5, P < 0.001). The clinical
symptoms in these patients were cholangitis or biliary sepsis in
50/90 cases (55.5%) and hepatic or thoracic abscesses in 40/
90cases (44.4%) (Table 3).Mycetomawas thefinal diagnosis in
3 (0.6%) cases. The final microbiological diagnosis of superin-
fection only was achieved in 25 (40.9%) superinfected hepatic
cysts versus 4 (44.0%) superinfected thoracic cysts.
The isolated bacterial organisms are shown in Figure 4. The
most frequently isolated microorganism was Escherichia coli
(7), followed by Staphylococcus aureus (6) and Staphylococcus
epidermidis (6). Polymicrobial infections were detected in 2
TABLE 1
Main clinical characteristics of the CE patients included in the present
study attending at the associated complications
Characteristics 506 patients, n (%)
Age, mean ± SD 59.3 ± 20.3
Male 298 (58.9)
Rural areas 351 (69.4)
Contact with animals 117 (23.1)
Other comorbidity 239 (47.2)
Cyst multiple 159 (31.4)
Cyst size mean ± SD
















Hyper-IgE (IgE > 100 UI/mL) 34 (6.7)
Curative treatment (surgery, surgery &
drugs, and puncture, aspiration,
injection, reaspiration)
356 (70.4)
Only medical treatment 17 (3.4)
Watch & wait 133 (26.3)
Recurrences 53 (10.5)
Overall mortality 81 (16.0)
Attributable mortality CE 14 (2.8)
Hospital stay, mean ± SD 16.3 ± 82.0
Hospitalization expense per individual of
the cohort* (V 404.69/day × 16.3 days)
6,596.45/patient
* Price per hospitalization per day of stay and occupied bed, according to the classification
of hospitals by sections, in the CAUSA (Section 1) = 404.69 V/day.
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(6.8%) patients. Aspergillus fumigatus was found in the patho-
logical anatomy of three patients with mycetoma. Antimicrobial
andsurgical agentswereused inall patients, andsurgical and/or
radiological drainage was used in 10 patients (10/90, 11.1%).
Immunoallergic complications. Other complications de-
tected in our cohortwere immunological reactions attributable
to CE in 17 (3.3%) patients (Table 2). Urticaria/angioedema
was the most frequently detected complication, observed in
9/17 cases (52.9%), followed by anaphylaxis in 6/17 cases
(35.3%) (Table 3). Patients with immunological reactions fre-
quently presented with hyper-IgE (> 100 UI/mL), eosinophilia
(> 450eosinophils/mm3), andseropositivity (hemagglutination
indirect title > 1/80) comparedwith the rest of the patients (P <
0.05). Surgical intervention for the cyst was performed in all 17
patients (100%) and in combination with antiparasitic drugs in
14 (82.3%) of them.
FIGURE 2. Main clinical manifestations associated with complications of CE (percentage was calculated on the 204 patients who had
complications).
FIGURE 3. Evolution of annual incidence rates (×105 person-years) of complications of CE during the period (1998–2017).
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Diseasemortalitywashigher inCEpatientswithmechanical
complications (9.4%) than in patients with infectious compli-
cations (5.6%) and in patientswith allergic complications (0%)
(OR = 19.7, 95% CI, 4.3–89.1, P < 0.001) (Table 2).
DISCUSSION
Although treatment of echinococcosis is not well defined,
antiparasitic drugs along with surgical procedures are usually
the first line of treatment. Nevertheless, CE surgery is fre-
quently associated with complications in clinical practice, in
which certain patients, especially the elderly with other
comorbidities, are treated based on “watch and wait.” In a
recent study, this treatment strategy was associated with
higher mortality attributable to CE complications.13
The spontaneous complications of CE have also been
commonly referred to in the literature, although their frequency
and risk factors involved have not been well established. We
aimed to study the spontaneous complications of CE. Thus,
we selected all the inpatients with a diagnosis of CE, and we
studied the patients showing symptoms attributable to the
complications of cysts during follow-up.
Because CE is usually an asymptomatic parasitic infection,
we considered CE patient to have complications if the patient
presented symptoms, clinical signs, or radiological findings
attributable to CE. In our study, we excluded secondary
complications due to a surgical procedure.
First, we detected a low complication rate, showing that CE
complications are rare in our area, despite a high prevalence
found in a previous report.15
Nevertheless,whenwe focusedonpeople infectedwithCE,
the complication rate was above 40%. These data are higher
than those shown by other groups. Despite the selection bias,
TABLE 2
Association analysis of the main complications of CE (dependent variable) and the clinical variables (independent variables) included in this study
Independent variables
Mechanical complications (N = 127) Infectious complications (N = 90) Allergic complications (N = 17)
n (%) P-value* Or (95% CI) n (%) P-value* Or (95% CI) n (%) P-value* Or (95% CI)
Gender, male 80 (63.0) 0.278 1.2 (0.8–1.9) 52 (57.8) 0.793 0.9 (0.6–1.5) 11 (64.7) 0.627 1.3 (0.5–3.5)
Age, ³ 60 years 66 (52.0) 0.144 0.7 (0.5–1.1) 56 (62.2) 0.310 1.3 (0.8–2.0) 2 (11.8) < 0.001* 0.1 (0.0–0.4)
Rural areas 96 (75.6) 0.079 1.5 (0.9–2.4) 70 (77.8) 0.055 1.7 (0.9–2.9) 7 (41.2) 0.014* 0.6 (0.2–0.8)
Comorbidity 41 (32.3) < 0.001* 0.4 (0.3–0.6) 43 (47.8) 0.892 1.1 (0.6–1.6) 1 (5.9) 0.001* 0.1 (0.0–0.5)
Immunodepression 14 (11.0) 0.005* 0.4 (0.2–0.8) 15 (16.7) 0.439 0.8 (0.4–1.4) 0 0.038* –
Single cyst 86 (67.7) 0.809 1.1 (0.7–1.6) 64 (71.1) 0.588 1.1 (0.7–1.9) 8 (47.1) 0.050 2.5 (0.9–6.7)
Multiple cysts 41 (32.3) 26 (28.9) 9 (52.9)
Liver localization 87 (68.5) < 0.001* 0.3 (0.2–0.5) 75 (83.3) 0.993 1.0 (0.5–1.8) 16 (94.1) 0.226 3.2 (0.4–25.0)
Lung localization 33 (26.0) < 0.001* 3.1 (1.9–5.3) 14 (15.6) 0.652 1.1 (0.6–2.2) 1 (5.9) 0.324 0.4 (0.1–2.8)
Others localization 24 (18.9) 0.014* 2.0 (1.1–3.4) 11 (12.2) 0.887 0.9 (0.5–1.9) 1 (5.9) 0.392 0.4 (0.1–3.2)
Size cyst < 7 cm 67 (53.6) 0.973 1.0 (0.7–1.5) 36 (42.4) 0.024* 1.7 (1.1–2.7) 10 (58.8) 0.652 1.2 (0.5–3.3)
Size cyst > 7 cm 58 (46.4) 49 (57.6) 7 (41.2)
WHO-1 6 (6.9) 0.084 – 4 (5.3) 0.812 – 1 (6.3) 0.160 –
WHO-2 29 (33.3) 22 (29.3) 4 (25.0)
WHO-3 15 (17.2) 12 (16.0) 5 (31.3)
WHO-4 11 (12.6) 13 (17.3) 0
WHO-5 26 (29.9) 24 (32.0) 6 (37.5)
Positive serology
(> 1/80)
55 (43.3) 0.010* 1.7 (1.1–2.6) 36 (40.0) 0.190 1.4 (0.8–2.2) 13 (76.5) < 0.001* 6.7 (2.1–20.9)
Hyper-IgE 9 (7.1) 0.159 4.3 (0.5–38.1) 6 (6.7) 0.854 1.2 (0.2–6.7) 10 (58.8) 0.028* 0.7 (0.5–0.9)
Pathological
eosinophilia (³ 450)
44 (36.4) 0.001* 2.2 (1.4–3.4) 30 (34.5) 0.022* 1.8 (1.1–2.9) 7 (46.7) 0.048* 2.7 (1.1–7.7)
Tumor associated 2 (1.6) 0.009* 0.2 (0.4–0.7) 3 (3.3) 0.175 0.4 (0.1–1.5) 0 0.267 –
Thrombosis associated 0 0.028* – 1 (1.1) 0.290 0.3 (0.1–2.7) 1 (5.9) 0.427 2.3 (0.3–18.5)





109 (85.8) < 0.001* 3.2 (1.9–5.5) 61 (67.8) 0.533 0.8 (0.5–1.4) 17 (100.0) 0.007* –
Drugs orWatch & Wait 18 (14.2) 29 (32.2) 0
Recurrences 14 (11.0) 0.815 1.1 (0.6–2.1) 11 (12.2) 0.555 1.2 (0.6–2.5) 3 (17.6) 0.328 1.8 (0.5–6.7)
Cohort mortality 18 (14.2) 0.515 0.8 (0.5–1.5) 17 (18.9) 0.416 1.3 (0.7–2.3) 0 0.067 –
CE disease mortality 12 (9.4) < 0.001* 19.7 (4.3–89.1) 5 (5.6) 0.076 2.6 (0.8–8.1) 0 0.479 –
* Statistical significance level of 5% (P < 0.05).
TABLE 3
Description of the main types of complications associated with CE
Type of complications N = 506 patients n (%)












Portal hypertension 2 (0.4)
Cyst rupture 15 (2.9)
Cyst rupture 14
Collapse middle lobe 1
Infectious complications 90 (17.8)
Cholangitis or biliary sepsis 50
Superinfection of CE 40




632 COLLADO-ALIAGA AND OTHERS
the results exclusively from inpatients suggest that patients
with CE had a high risk of developing illnesses associated
with CE.
In our work, we analyzed the variables associated with CE
complications, and we found that younger patients presented
a higher rate of complications than older patients did. This
result could be due to a longer follow-up in younger people
than in the elderly. Moreover, we detected that patients from
rural areas had a higher rate of complications than did patients
from urban areas. Patients in rural areas tend to have less
access to health services than the urban population does and,
consequently, rural residents may receive a late diagnosis
when CE is diagnosed by a complication.
Regarding the characteristics of CE, we found a higher rate
of CE complications located in the liver than in other locations.
Other characteristics of CE, such as size or WHO stage, were
not associated with a higher rate of CE complications. These
results support the notion that the size and/or earlier WHO
stage of CE is not useful for discriminating between patients
who must undergo a surgical procedure and those who can
wait.
The complications detected could be classified by their
pathogenesis into the following: mechanical, which were
caused by rupture (with frequent occurrence of fistula) or
compression of the structures next to the cyst, superinfection,
caused by involvement of microorganisms, and immuno-
logical, due to immunoallergic reactions attributable to
echinococcosis.
Among all patients in our cohort, mechanical complications
were the most frequently detected. The rupture of a liver or
thoracic cyst, and consequently the occurrence of fistulas in
the biliary tract, bronchial tree, or pleura, were detected in
88/506 (17.4%) patients. Postsurgery fistulas have been fre-
quently described in the literature.16 In our study, we showed
that this is the main spontaneous complication of echino-
coccosis. Other studies showed that the rupture of CE into the
biliary tract occurs in 9% of operated patients because of
hydatid cysts.17,18
Peritoneal, pleural, pericardial, and cutaneous fistulas have
been described in the literature, although these are less fre-
quent.Wedid not find an association between the presence of
fistulas and patient characteristics, such as gender, age, and
comorbidities.
We analyzed the association between fistulas and infection
rate. More than 30% of patients with fistulas were super-
infected. It was difficult to determine which was the first
pathogenic mechanism, fistula or superinfection. However,
we observed an association with a larger size and a less ad-
vancedWHOstage. These results support the hypothesis that
the ruptured cysts are frequently caused by high superficial
tension in the wall of a large cyst; however, rupture has also
been described after hard external traumatism.19
Other mechanical complications detected in our cohort
were due to direct compression of the structures adjacent to
CE cysts. The heart, central nervous system, or other main
organs can become affected, especially in CE cysts of large
size, causing arrhythmia and heart failure,20 headache, epi-
lepsy, or paralysis.21
In our work, one patient had a spell of medullary syndrome
caused by an intramedullary CE cyst. Because of slow growth
in the liver, there are no complications until the cysts reach a
large size. In our cohort, we detected two patients with portal
hypertension in the clinical setting. Theonset symptom inboth
patients was a variceal hemorrhage with portal vein cav-
ernomatosis. Among the literature, only our study detected
cases with these complications. It is possible that compres-
sion of the vena cava and portal vein thrombosis led to portal
hypertension and secondary portal cavernomatosis, as pre-
sented in two previous patients.22
The secondmost frequent complicationwas superinfection
of CE. In previous works, the rate of superinfection in hydatid
cysts ranged from 1% to 8%, but these studies were
FIGURE 4. Microorganisms identified regarding the location of infection. This figure appears in color at www.ajtmh.org.
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specifically designed to evaluate this complication, and the
inclusion criteria were not well defined.23–25 Our group con-
ducted a retrospective study in 2009 that included patients
with positive cultures or purulent drainage and included 37
cases in 12 years.26Gram-positive cocci,Enterobacteriaceae,
and Aspergillus spp. were the most prevalent pathogens in
both hepatic and pulmonary cysts, but because of the char-
acteristics of the study, we did not establish the frequency or
the risk factors involved. Thus, in the present study with a
cohort of inpatients, we detected more than 14% of patients
with superinfection. Several bacterial or fungal superinfec-
tions were found in patients with CE from sites close to the
hydatid cyst (e.g., biliary or bronchial tree). In these cases, a
macroscopic or microscopic rupture of the wall cyst is in-
volved in the pathogenesis. In this sense, above one-third
of patients with superinfection presented with biliary or
bronchial-associated fistulas. Moreover, it is possible that the
cyst promotes superinfection by compression and distortion
of the biliary tree.
On the other hand,microorganisms can bedisseminated by
bacteremia from adistant location causingCE infection. In our
study, we detected six patients with superinfection by
S. aureus, which colonizes the upper respiratory tract. The
classic risk factors for bacteremia, such as diabetes mellitus,
the use of steroids, renal failure, neoplasia, or HIV, were found
in 23/204 patients; however, we did not detect statistically
significant associations of these factors with superinfection.
The different types of microorganisms involved according
to the location of the cyst and its clinical manifestations are
another point of interest in our cohort. We found that although
thepatientswith bacterial superinfection presentedwith fever,
local pain, andother pulmonary cysts infectedwithAspergillus
spp., the patients in this study were asymptomatic at di-
agnosis. Kocer et al. described that 2% of patients with tho-
racic hydatidosis have a superinfection with Aspergillus spp.
andpresentwith symptomsof cough, hemoptysis, chest pain,
and fever.27
Another classic complication is the immune or hypersen-
sitive reaction28 with a wide variety of symptoms ranging from
skin manifestations, such as urticaria/angioedema, or re-
spiratory symptoms, such as asthma, to the most severe
cases, such as anaphylactic shock. First, we found a low rate
of this type of complication, with urticaria/angioedema being
the most frequent, followed by anaphylactic shock and
asthma. In vitro and in vivo studies have shown that proto-
scolex and somatic antigens can activate the alternative
complement pathwaysC3a,C4a, andC5a,whichbind tomast
cell receptors causing degranulation. Consequently, hista-
mine and other vasoactive amines are released, causing
anaphylactic reactions.29,30 These reactions have also been
described in other helminthic infections, such as canine
dirofilariasis.31
On the other hand, it is possible that another IgE-based
classic mechanism of allergy blinded to molecular EgEF-1
beta/delta is involved.32 In our cohort, patients with immu-
nological reactions frequently displayed hyper-IgE eosino-
philia and seropositivity. In previously published studies,
a positive correlation was found between the IgE levels
and disease severity and/or progression/regression after
treatment.33,34
A limitation of this work is the selection bias because the
cases included in the study were inpatient. Therefore,
asymptomatic patients are usually diagnosed with inci-
dentaloma. It is possible that the frequency of complications
described in this manuscript is too minor to discuss. There-
fore, it is very difficult to estimate the actual prevalence of the
disease and the actual percentage of spontaneous compli-
cations, as many asymptomatic individuals will remain
undetected.
In summary, there were frequent complications in the cur-
rent cohort of patients with CE, especially in the liver cysts of
younger patients, regardless of other variables, such as size or
stage of the cyst. Mechanical complications and superinfec-
tion were the most frequent complications. Patients in en-
demic areas with urticarial and anaphylactic reactions of
unknown cause should be tested for CE.
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17. Köksal N, Müftüoglu T, Günerhan Y, Uzun MA, Kurt R, 2001.
Management of intrabiliary rupturedhydatiddiseaseof the liver.
Hepatogastroenterology 48: 1094–1096.
18. Paksoy M, Karahasanoglu T, Carkman S, Giray S, Senturk H,
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